Gender-related risk of myocardial involvement in systemic amyloidosis

References

• Park M A, Mueller P S, Kyle R A, Larson D R, Plevak M F, Gertz M A. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003; 82: 291–298
   PubMed Web of Science ®Google Scholar
• Witzig T E, Gertz M A, Lust J A, Kyle R A, O'Fallon W M, Greipp P R. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996; 88: 1780–1787
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Gertz M A, Kyle R A. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998; 104: 232–237
   PubMed Web of Science ®Google Scholar
• Kyle R A, Therneau T M, Rajkumar S V, Remstein E D, Offord J R, Larson D R, Plevak M F, Melton L J. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102: 3759–3764
   PubMed Web of Science ®Google Scholar
• Berk J L, Keane J, Seldin D C, Sanchorawala V, Koyama J, Dember L M, Falk R H. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003; 124: 969–977
   PubMed Web of Science ®Google Scholar
• Alves M, Conceicao I, Luis M L. Neurophysiological evaluation of sexual dysfunction in familial amyloidotic polyneuropathy – Portuguese type. Acta Neurol Scand 1997; 96: 163–166
   PubMed Web of Science ®Google Scholar
• Bittencourt P L, Couto C A, Clemente C, Farias A Q, Palacios S A, Mies S, Goldberg A C. Phenotypic expression of familial amyloid polyneuropathy in Brazil. Eur J Neurol 2005; 12: 289–293
   PubMed Web of Science ®Google Scholar
• Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan. Clinical and genetic heterogeneity. Neurology 2002; 58: 1001–1007
   PubMed Web of Science ®Google Scholar
• Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, Takei Y, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G. Late-onset familial amyloid polyneuropathy type I (transthyretin met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan: clinicopathological and genetic features. Brain 1999; 122: 1951–1962
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, Said G, Bonay ti-Pellié G. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003; 40: e120
   PubMed Web of Science ®Google Scholar
• Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 1057–1062
   PubMed Web of Science ®Google Scholar
• Falk R H. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112: 2047–2060
   PubMed Web of Science ®Google Scholar
• Kyle R A, Spittell P C, Gertz M A, Li C Y, Edwards W D, Olson L J, Thibodeau S N. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996; 101: 395–400
   PubMed Web of Science ®Google Scholar
• Ng B, Connors L H, Davidoff R, Skinner M, Falk R H. Senile systemic amyloidosis presenting with heart failure. A comparison with light chain-associated amyloidosis. Arch Intern Med 2005; 165: 1425–1429
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Perugini E, Salvi F. Female sex as a possible protective factor from myocardial involvement in transthyretin-related amyloidoses. Arch Intern Med 2005; 165: 2429
   PubMedGoogle Scholar
• Lachmann H J, Booth D R, Booth S E, Bybee A, Gilbertson J A, Gillmore J D, Pepys M B, Hawkins P N. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346: 1786–1791
   PubMed Web of Science ®Google Scholar
• Ferlini A, Fini S, Salvi F, Patrosso M C, Vezzoni P, Forabosco A. Molecular strategies in genetic diagnosis of transthyretin-related hereditary amyloidosis. FASEB J 1992; 6: 2864–2866
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 2006; 136: 715–720
   PubMed Web of Science ®Google Scholar
• Gertz M A, Comenzo R, Falk R H, Fermand J P, Hazenberg B P, Hawkins P N, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005; 79: 319–328
   PubMed Web of Science ®Google Scholar
• Coutinho P, Martins da Silva A, Lopes Lima J, Resende, Barbosa A. Forty years of experience with type I amyloid neuropathy. Amyloid and amyloidosis, G G Glenner, P P Costa, A F Freitas. Excerpta Medica, Amsterdam 1980; 88–98
   Google Scholar
• Rapezzi C, Perugini E, Salvi F, Grigioni F, Riva L, Cooke R M, Ferlini A, Rimessi P, Bacchi-Reggiani L, Ciliberti P, Pastorelli F, Leone O, Bartolomei I, Pinna A D, Arpesella G, Branzi A. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies?. Amyloid 2006; 13: 143–153
   PubMed Web of Science ®Google Scholar
• Cheitlin M D, Armstrong W F, Aurigemma G P, Beller G A, Bierman F Z, Davis J L, Douglas P S, Faxon D P, Gillam L D, Kimball T R, Kussmaul W G, Pearlman A S, Philbrick J T, Rakowski H, Thys D M, Antman E M, Smith S C, Jr, Alpert J S, Gregoratos G, Anderson J L, Hiratzka L F, Hunt S A, Fuster V, Jacobs A K, Gibbons R J, Russell R O, American College of Cardiology; American Heart Association; American Society of Echocardiography. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108: 1146–1162
   PubMed Web of Science ®Google Scholar
• Devereux R B, Alonso D R, Lutas E M, Gottlieb G J, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458
   PubMed Web of Science ®Google Scholar
• Garcia M J, Thomas J D, Klein A L. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32: 865–875
   PubMed Web of Science ®Google Scholar
• Falk R H, Comenzo R L, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898–909
   PubMed Web of Science ®Google Scholar
• Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S, Rapezzi C, Bacchi Reggiani M L, Marinelli G. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J 2004; 25: 1237–1241
   PubMed Web of Science ®Google Scholar
• Kawamura S, Takahashi M, Ishihara T, Uchino F. Incidence and distribution of isolated atrial amyloid: histologic and immunohistochemical studies of 100 aging hearts. Pathol Int 1995; 45: 335–342
   PubMed Web of Science ®Google Scholar
• Rocken C, Peters B, Juenemann G, Saeger W, Klein H U, Huth C, Roessner A, Goette A. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002; 106: 2091–2097
   PubMed Web of Science ®Google Scholar
• Goette A, Rocken C. Atrial amyloidosis and atrial fibrillation: a gender-dependent ‘arrhythmogenic substrate’?. Eur Heart J 2004; 25: 1185–1186
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, Solinas P, Gorini M, Maggioni A P, MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38: 1829–1835
   PubMed Web of Science ®Google Scholar
• Devereux R B, Lutas E M, Casale P N, Kligfield P, Eisenberg R R, Hammond I W, Miller D H, Reis G, Alderman M H, Laragh J H. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222–1230
   PubMed Web of Science ®Google Scholar
• Liao Y, Cooper R S, Mensah G A, McGee D L. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation 1995; 92: 805–810
   PubMed Web of Science ®Google Scholar
• Coe J E, Ross M J. Hamster female protein, a sex-limited pentraxin, is a constituent of Syrian hamster amyloid. J Clin Invest 1985; 76: 66–74
   PubMed Web of Science ®Google Scholar
• Coe J E, Ross M J. Amyloidosis and female protein in the Syrian hamster: concurrent regulation by sex hormones. J Exp Med 1990; 171: 1257–1267
   PubMed Web of Science ®Google Scholar
• Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, Harada N, Zhong Z, Shen Y, Li R. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci USA 2005; 102: 19198–19203
   PubMed Web of Science ®Google Scholar
• Barron A M, Fuller S J, Verdile G, Martins R N. Reproductive hormones modulate oxidative stress in Alzheimer's disease. Antioxid Redox Signal 2006; 11: 2047–2059
   Google Scholar
• Petanceska S S, Nagy V, Frail D, Gandy S. Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain. Neurology 2000; 54: 2212–2217
   PubMed Web of Science ®Google Scholar